Efficacy of pregabalin in the treatment of generalized anxiety disorder - Double-blind, placebo-controlled comparison of BID versus TID dosing

被引:137
作者
Pohl, RB
Feltner, DE
Fieve, RR
Pande, AC
机构
[1] Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA
[2] Wayne State Univ, Univ Psychiat Ctr, Detroit, MI USA
关键词
D O I
10.1097/01.jcp.0000155820.74832.b0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pregabalin is a new anxiolytic that acts as a presynaptic inhibitor of the release of excessive levels of excitatory neuro-transmitters by selectively binding to the alpha(2)-delta subunit of voltage-gated calcium channels. The current study evaluated the anxiolytic efficacy of BID versus TID dosing of pregabalin in patients with generalized anxiety disorder. Outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition generalized anxiety disorder and having baseline Hamilton Anxiety (HAM-A) total scores >= 20 were randomized to 6 weeks of double-blind treatment with pregabalin 200 mg/d (BID; N = 78), 400 mg/d (BID; N = 89), or 450 mg/d (TID; N = 88) or placebo (N = 86). Mean improvement in HAM-A total score at last observation carried for-ward end point was significantly greater on pregabalin 200 (P = 0.006), 400 (P = 0.001), and 450 mg/d (P = 0.005) compared with placebo. Pairwise comparisons of BID versus TID dosing found no difference in HAM-A change score at end point. All 3 pregabalin dosage groups showed significantly greater efficacy versus placebo at end point on the HAM-A psychic and somatic anxiety factor scores. Improvement on both factors was rapid: significance versus placebo was achieved as early as the first assessment at week 1, with >= 30% reduction in HAM-A severity and equal or greater improvement for every subsequent visit in >= 38% of patients in all 3 pregabalin dosage groups (P <= 0.001). Pregabalin was well tolerated, and despite the fixed-dose study design, discontinuations caused by adverse events ranged from 9% to 13%-comparable with that observed with placebo (8%). This study demonstrates that pregabalin is an effective treatment of generalized anxiety disorder, with BID dosing showing similar efficacy and comparable tolerability with TID dosing.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 49 条
[1]   Efficacy of sertraline in a 12-week trial for generalized anxiety disorder [J].
Allgulander, C ;
Dahl, AA ;
Austin, C ;
Morris, PLP ;
Sogaard, JA ;
Fayyad, R ;
Kutcher, SP ;
Clary, CM .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (09) :1642-1649
[2]   Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder - Twenty-four-week placebo-controlled dose-ranging study [J].
Allgulander, C ;
Hackett, D ;
Salinas, E .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 :15-22
[3]   Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures [J].
Arroyo, S ;
Anhut, H ;
Kugler, AR ;
Lee, CM ;
Knapp, LE ;
Garofalo, EA ;
Messmer, S .
EPILEPSIA, 2004, 45 (01) :20-27
[4]   HYPNOTICS AND SLEEP PHYSIOLOGY - A CONSENSUS REPORT [J].
BORBELY, AA ;
AKERSTEDT, T ;
BENOIT, O ;
HOLSBOER, F ;
OSWALD, I .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1991, 241 (01) :13-21
[5]   Pharmacologic treatment of generalized anxiety disorder [J].
Brawman-Mintzer, O .
PSYCHIATRIC CLINICS OF NORTH AMERICA, 2001, 24 (01) :119-+
[6]  
BRYANS JS, 1999, MED RES REV, V16, P519
[7]  
Busch Janice A., 1998, Epilepsia, V39, P58
[8]   DOUBLE-BLIND COMPARISON OF BUSPIRONE AND CLORAZEPATE IN ANXIOUS OUTPATIENTS [J].
COHN, JB ;
BOWDEN, CL ;
FISHER, JG ;
RODOS, JJ .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (3B) :10-16
[9]  
COLE JO, 1993, J CLIN PSYCHIAT, V54, P49
[10]  
CULPEPPER L, 2003, ANN M ANX DIS ASS AM